GlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an immuno-oncology drug that made a splash at last year’s ESMO meeting.
AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business and form a joint venture with combined annual sales
GlaxoSmithKline plans to carry out clinical trials on its pancreatic drug hopeful, GSK547, following promising results when treating mice and laboratory-grown tumour cells.
AstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide clarity on future trading relations, according to press reports.